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Background: The use of the vancomycin wrap to pretreat the hamstring graft in anterior cruciate ligament reconstruction (ACLR)
has grown in popularity since it was first described in 2012 and has significantly reduced rates of postoperative infection. How-
ever, it remains unknown if this antibiotic treatment affects the molecular composition of the graft.
Purpose: To establish whether treatment with vancomycin at 5 mg/mL, the most commonly used concentration, alters the molec-
ular function of the hamstring graft in ACLR.
Study Design: Controlled laboratory study.
Methods: Surplus hamstring tendon collected after routine ACLR surgery was used for in vitro cell culture and ex vivo tissue
experiments. Vancomycin was used at 5 mg/mL in RPMI or saline diluent to treat cells and tendon tissue, respectively, with dil-
uent control conditions. Cell viability at 30, 60, and 120 minutes was assessed via colorimetric viability assay. Tendon cells treated
with control and experimental conditions for 1 hour was evaluated using semiquantitative reverse transcription analysis, immu-
nohistochemistry staining, and protein quantitation via enzyme-linked immunosorbent assay for changes in apoptotic, matrix,
and inflammatory gene and protein expression.
Results: Vancomycin treatment at 5 mg/mL significantly reduced tenocyte viability in vitro after 60 minutes of treatment (P\ .05);
however, this was not sustained at 120 minutes. Vancomycin-treated tendon tissue showed no significant increase in apoptotic
gene expression, or apoptotic protein levels in tissue or supernatant, ex vivo. Vancomycin was associated with a reduction in
inflammatory proteins from treated tendon supernatants (IL-6; P \ .05).
Conclusion: Vancomycin did not significantly alter the molecular structure of the hamstring graft. Reductions in matrix protein
and inflammatory cytokine release point to a potential beneficial effect of vancomycin in generating a homeostatic environment.
Clinical Relevance: Vancomycin ACL wrap does not alter the molecular structure of the ACL hamstring graft and may improve
graft integrity.
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Anterior cruciate ligament (ACL) reconstruction (ACLR)
using patellar and hamstring tendon grafts is a relatively
routine and successful surgical procedure, with low
reported levels of infection (0.14%-1.8%).9,18,31 As with all
orthopaedic surgery involving implants or grafts, it is rou-
tine to administer prophylactic antibiotics before the proce-
dure to reduce the risk of infection and septic arthritis,
potentially serious complications.10 Although the ideal
timing of administration has been debated, it is common
practice to administer them before skin incision and tour-
niquet inflation.7,8
The most common pathogen cultured in synovial fluid
after ACLR infection is coagulase negative Staphylococcal
species, generally thought to be a contamination of the
graft from either patient skin or graft preparation.23 This
suggests that targeting the graft, as a source of infection,
with antimicrobials would be an efficient way to reduce
postoperative infection rates.
Vancomycin is a glycopeptide antibiotic originally intro-
duced to treat methicillin-resistant Staphylococcus aureus
and coagulase negative Staphylococcal species with proven
bactericidal activity. The minimum inhibition concentration
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required for Staphylococcus aureus is 0.5 mg/mL and is in
the range of 0.25 mg/mL to 2.0 mg/mL for other bacteria.3
It is widely used in many forms in orthopaedic surgery
(bone cement in routine arthroplasty, intravenous (IV) infu-
sion to treat prosthetic joint infection, and topical powder on
spinal surgery wounds), with results showing that it
reduces infection significantly.21,24 A number of other surgi-
cal specialties utilize antibiotics and antimicrobials, either
topically on wounds or in solution to immerse and wrap
implants before surgery, and reports have shown significant
reductions in infection.11,30,33 Cardiothoracic surgery has
been at the forefront of this, with surgeons applying vanco-
mycin powder to sternotomy wounds following the results of
a seminal paper in 198933 and now implanting cardiac elec-
tronic devices enveloped in a degradable antimicrobial
sleeve.30
The specific practice of wrapping the donor graft in
a vancomycin-soaked sterile swab before insertion in
ACLR surgery has steadily increased since 2012 when
the ‘‘vancomycin wrap’’ was first described.34 Since then,
there have been a number of published studies and reviews
that have demonstrated significantly reduced postopera-
tive infection rates in ACLR.5,14,19,25-27,34
The molecular effects of vancomycin on human and animal
periarticular tissues, including tendon, has a limited evidence
base. Porcine chondrocyte death was significantly increased
after exposure to vancomycin at doses of 5 mg/mL or higher.29
A human in vitro study has shown vancomycin toxicity to
chondrocyte and osteoblast-like cells, via a reduction in cell
DNA, at doses of 250 mg/mL and 125 mg/mL for osteoblast
and chondrocytes, respectively, after 48 hours of treatment.4
Two further studies have concluded that vancomycin is not
toxic at doses up to 16 mg/mL for 36 hours in an ex vivo chon-
drocyte model12 and up to 1000 mg/mL for 72 hours in an in
vitro osteoblast model.13 Porcine tendon models show that
vancomycin is effective at eliminating bacterial contamina-
tion at 5 mg/mL after 20 minutes of soaking and that it has
no effect on the biomechanical properties at doses up to
10 mg/mL.28 Bovine studies have demonstrated that tendon
can act as a reservoir for vancomycin, releasing the antibiotic
for up to 24 hours into the joint, changing a source of infection
into an intra-articular prophylactic vehicle.15
The current study aimed to determine whether treat-
ment with vancomycin at 5 mg/mL, the clinically used con-
centration, alters the structural or molecular function of
the hamstring graft in ACLR using human tendon in vitro
and ex vivo models.
METHODS
Tissue Collection and Preparation
Surplus human tendon tissue was obtained during surgery
for ACL hamstring reconstruction. Patients were screened
and the tissue discarded if there was a history of surgery to
that joint, infection, or malignancy. The tissue was used for
ex vivo and in vitro experiments as outlined below. Tissue
collection complied with local research ethics committee
approval. All tissue was collected under ethics REC 14/
WS/1035.
Tissue Culture
Tenocyte cells were derived from surplus hamstring tendon
tissue. Cell culture was maintained for 28 days in RPMI
supplemented with 10% fetal calf serum, 100 U/mL penicil-
lin, 100 mg/mL streptomycin (Gibco), at 37C in a humidified
atmosphere of 5% CO2. Cells were passaged with trypsin at
subconfluency and used at second or third passage for in
vitro experiments.
Surplus tendon tissue from separate donors was cut into
1-cm sections for ex vivo experiments. These sections were
treated with vehicle control and experimental conditions
for 1 hour at 37C in a humidified atmosphere of 5%
CO2. Supernatants were aspirated and stored for future
protein analysis and replaced with RPMI for 16 hours of
culture to allow for gene expression changes and cytokine
release. After the 16-hour incubation, supernatants were
aspirated and stored for future analysis and the tendon tis-
sue was transferred to RNALater (Ambion) or 4% buffered
formalin for quantitative polymerase chain reaction
(qPCR) and immunohistochemistry analysis, respectively.
Cell Viability Assay
To assess the effect of vancomycin on tenocytes, cells were
exposed to the clinically relevant concentration of 5 mg/mL
of vancomycin for up to 120 minutes. The in vitro effect
was evaluated using 3-(4,5-dimethylthiazol-2-Yl)-2,5-
diphenyltetrazolium bromide cell viability assays (MTT;
Sigma Aldrich). Tenocytes were plated at 25,000 cells/well
in a 24-well plate for 48 hours at 37C, 5% CO2, before use.
The culture media was aspirated and discarded and replaced
with RPMI control and experimental conditions, vancomycin
5 mg/mL in RPMI diluent for 30, 60, and 120 minutes at
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37C, 5% CO2. Supernatants were aspirated and replaced
with sterile filtered MTT for 3 hours. Cells were then washed
with sterile RPMI and incubated with DMSO for 10 minutes
to dissolve the formazan product. This was transferred into
a 96-well plate (100 mL per well in duplicate) and read on
an MTX TC II microplate reader (Dynex Technologies) at
540 nm.
Gene Expression Analysis via qPCR
Vancomycin-treated, vehicle control, and untreated tendon
explant tissue in RNALater (Ambion) from 5 donors was
used for qPCR analysis. The untreated condition allowed
for any gene expression changes already present in the ten-
don to be evaluated. RNA was extracted using PureLink
RNA Mini Kit (Thermo Fisher) as per the manufacturer’s
instructions. The High Capacity cDNA Reverse Transcrip-
tion Kit (Thermo Fisher) was used to prepare cDNA as
per the manufacturer’s instructions on a thermal cycler
(Applied Biosystems). PCR analysis was performed with
PowerUP SYBER Green Master Mix (Thermo Fisher), in
duplicate. Primers (Integrated DNA Technologies) are listed
in Appendix 1 (available in the online version of this article).
The gene expression of 9 genes involved in the intrinsic and
extrinsic apoptotic pathways and extracellular matrix pro-
tein collagen 1a were assessed.
Enzyme-Linked Immunosorbent Assay (ELISA)
Quantitation of the inflammatory proteins interleukin 6
(IL-6), interleukin 8 (IL-8), MMP3, CCL2; extracellular
matrix protein collagen 1a; and mitochondrial signally
apoptotic protein cytochrome C were determined in super-
natants from control and treated tendon explants with
vancomycin 5 mg/mL in 0.9% saline diluent, using ELISAs
as per the manufacturer’s instructions (IL-6, IL8, MMP3,
CCL2, Cytochrome C Invitrogen Cytoset; Thermo Fisher;
and Pro Collagen 1a DuoSet; R&D Systems). Samples
were run in duplicate on a 96-well plate and read on an
MTX TC II microplate reader (Dynex Technologies).
Caspase 3 Luminescence
Caspase 3 is an enzyme common to both intrinsic and
extrinsic apoptosis pathways. Levels of cleaved caspase 3
in supernatants from treated and control tendon explants
were determined by luminescence assay (Caspase-GLO 3/
7; Promega) as per the manufacturer’s instructions. Super-
natant was diluted 1:1 with Caspase-GLO 3/7 reagent,
incubated for 1 hour at room temperature, and the lumi-
nescence detected on a MicroBeta TriLux 1450 plate
reader (Perkin Elmer Life Sciences). All samples were
run in duplicate.
Histology and Immunohistochemistry
Treated and control tendon explant tissue, fixed in 4%
buffered formalin and embedded in paraffin, was immuno-
histochemically stained for caspase 3 (Cell Signaling Tech-
nology). Sections of tissue were cut to 5-mm thickness
(Leica Microsystems), paraffin removed by xylene, and
rehydrated in graded alcohol.
Endogenous peroxidase activity was quenched with 3%
(vol/vol) H2O2, and nonspecific antibody binding was
blocked with 2.5% horse serum in tris-buffered saline
(TBST) buffer for 30 minutes. Antigen retrieval was per-
formed in 0.01 M citrate buffer for 25 minutes in a micro-
wave. Tissue sections were incubated with primary
antibody diluted 1:125 in 2.5% (w/v) horse serum/TBST
overnight at 4C. After 2 washes, the slides were incubated
with a Vector ImmPRESS Reagent kit as per the manufac-
turer’s instructions for 30 minutes. The slides were washed
and incubated with Vector ImmPACT DAB chromagen
solution (1 drop per 1 mL diluent) for 30 seconds, followed
by extensive washing with water. Finally, the sections
were counterstained with hematoxylin, dehydrated in
graded alcohol, and mounted in DPX with a coverslip.
Tissue sections were imaged under a light microscope
(DP22; Olympus) at 10 3 and 40 3 magnification and com-
pared with Isotype controls. Quantification of staining was
performed in 2 stages. First, semiquantitative staging was
performed on 5 random high-powered fields, grading the per-
centage of positively stained cells in the filed using the Mod-
ified Bonar Score (grade 0, no staining; grade 1, 1%-10% of
cells stained positive; grade 2, 10%-20% of cells stained posi-
tive; grade 3, .20% of cells stained positive).
Second, the total number of positive and negative
stained cells in each of the 5 high-powered fields was
counted to generate the mean percentage positive for
stained cells.
Statistical Analysis
GraphPad Prism software (Version 6) was used for all statis-
tical analyses, and data were reported as mean and standard
error of the mean unless stated otherwise. Comparisons
between treatment groups were made using 1-way analysis
of variance or Student t test. Multiple comparisons were per-
formed between the untreated tendon and tendon treated
with vancomycin in saline compared with tendon in saline
alone, as this is current clinical practice.
RESULTS
Cell Viability and Apoptosis
Vancomycin treatment for 60 minutes resulted in a small
but significant reduction in tenocyte viability, in vitro,
compared with RPMI-treated control cells (P \ .05). How-
ever, this was not the case with treatment at 30 and 120
minutes (Figure 1A).
Although there was only a limited effect of vancomycin on
tenocyte viability, we assessed the cellular effect of vancomy-
cin on the tendon graft by evaluating apoptotic proteins cyto-
chrome C and caspase 3. After the ex vivo treatment, no
significant increase of cytochrome C in supernatants of ten-
don explants was measured at 1 hour after treatment with
vancomycin compared with saline (Figure 1B). In addition,
there was also no significant increase in cytochrome C
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measured in supernatants of explant tendon at 16 hours
after the 1-hour exposure to vancomycin (Figure 1B).
We assessed caspase 3 expression and protein quantita-
tion in supernatant by ELISA and tissue by immunohisto-
chemistry (IHC) staining, after vancomycin treatment.
IHC staining showed that vancomycin treatment resulted
in no disruption to the uniform collagen structure of ten-
don and suggested a trend toward more positive staining
for caspase 3 in the vancomycin-treated tissue, but this
was not significant (Figure 1, C and D). However, there
was a significant reduction in caspase 3 in tendon explant
supernatants after vancomycin treatment compared with
saline-treated control explants (Figure 1E).
The expression of 9 apoptotic genes was also measured
after ex vivo treatment of tendon with experimental condi-
tions. All results were normalized to fresh untreated graft
tendon. There was no significant increase in pro-apoptotic
genes with vancomycin treatment compared with untreated
or saline-treated tendon (Figure 2). There was a significant
reduction in expression of caspase 3 and BAX with vancomy-
cin treatment compared with untreated explants (Figure 2).
Matrix Protein Expression
Vancomycin treatment caused no significant changes in ten-
don matrix gene expression by measuring the expression of
Figure 1. (A) Viability of tenocytes after vancomycin treatment. Data are expressed as percentage change in cell viability com-
pared with untreated cells. N = 6, 30 and 60 minutes; N = 4, 120 minutes; analysis of variance, *P \ .05. (B) Cytochrome C quan-
titative enzyme-linked immunosorbent assay on tendon supernatants, after 1 hour of vancomycin treatment. N = 3. (C)
Quantitative expression of caspase 3, mean percentage of cells positive per treatment condition based on 5 high-power fields.
N = 5. (D) Caspase 3 immunohistochemistry staining of human tendon explant, treated with experimental conditions for 1 hour,
isotype rabbit IgG bottom smaller image shown in left corner of x10 image. (E) Caspase 3 luminesce in tendon supernatants after
1 hour of vancomycin treatment. N = 6; *P \ .05. Data are shown as mean 6 SEM.
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genes collagen 1a, collagen 3a, decorin, and tenascin C.
There was a significant reduction in collagen 1a protein in
supernatants from tendon treated with vancomycin com-
pared with those treated with saline alone (Figure 3).
Inflammatory Protein Release
Ex vivo vancomycin treatment of tendon showed a significant
reduction in the level of inflammatory cytokine IL-6 being
released into the supernatant when compared with saline
treatment (Figure 4). No difference was observed in CCL2,
and although not statistically significant, there was a trend
toward a reduction in IL-8 and MMP3 measured in superna-
tants of vancomycin-treated explants compared with saline.
DISCUSSION
The first description of the ‘‘vancomcyin wrap’’ for ACLR was
in 2012; since then, a number of studies have demonstrated
its effectiveness in combination with usual IV antibiotic pro-
phylaxis at reducing postoperative infection rates to almost
0%.5,14,19,25-27,34 One study reported infection rates in the con-
trol group, treated with prophylactic IV antibiotics alone, as
1.4% (n = 285) compared with 0% in patients who were trea-
ted with prophylactic IV antibiotics in combination with van-
comycin wrap (n = 870).34 A further study that conducted
a postoperative follow-up of 1300 consecutive ACLRs using
the vancomycin wrap in combination with standard IV antibi-
otic prophylaxis reported zero postoperative infections against
a retrospective control group (n = 240) that reported infections
Figure 2. Vancomycin does not induce apoptosis in tendon anterior cruciate ligament graft. AIFM1, BAX, TNFr, Caspase 3,
FADD, FAS, FAS ligand, Survivin, and BCL2 gene expression in tendon explant at 16 hours after 1-hour vancomycin treatment.
Data are shown as mean 6 SEM, normalized to the untreated tendon, relative to the housekeeping gene. N = 5; *P \ .05 vs
untreated.
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in 2.4% of patients.27 A more recent study that looked at 1640
patients found the use of a vancomycin wrap during ACLR
was associated with a 10-fold reduction in postoperative infec-
tion (0.1% vs 1.2%).5
Our study is the first to evaluate the molecular and
structural effects that vancomycin has on a human ham-
string graft for ACLR. The results of the current work indi-
cate that vancomycin appears safe and has no detrimental
effects on the cellular or molecular structure of the tendon
graft used for ACLR.
The addition of vancomycin at the commonly used clin-
ical dose did result in a reduction in tenocyte viability at 60
minutes. It is common in an in vitro model to experience
biological variability and we did not see this reduction sus-
tained after 30 or 120 minutes of treatment. Previously
published literature that used the same assay to assess
chondrocyte viability found vancomycin to be safe at doses
up to 16 mg/L over 36 hours of treatment,12 above the min-
imum inhibitory concentration for Staphylococcus aureus.3
It remains unclear from the published literature how much
of the antibiotic is absorbed both by the sterile swab and by
the tendon itself and therefore what concentration the
tenocytes are exposed to. One study reported that the ster-
ile swab absorbs an average of 7 mL of the 100-mL solution
containing vancomycin at 5 mg/mL.34 Bovine studies spe-
cifically looking at absorbance and elution of vancomycin
from tendon have demonstrated that both of these charac-
teristics are affected by graft size and rinsing,15 which
occurs in clinical practice once implanted, with arthro-
scopic washout of the joint. It is challenging to develop
a model that accounts for all of these variables. We there-
fore submerged uniform size tendon explant pieces in van-
comycin or saline for 1 hour. This eliminated any effect
drying may have had on the tendon and was long enough
to encompass reported average times from graft harvest
to implantation of 30 minutes (range, 28-43 minutes).16
The graft was then cultured for up to 16 hours after 1
hour of treatment to assess the effect of vancomycin on ten-
don gene expression and cytokine release. We used this as
our ‘‘surgical scenario’’ model and believe this accurately
reflects current practice and gives confidence that our molec-
ular findings translate to everyday clinical practice.
Treatment with vancomycin did not appear to initiate
cell death as there was no increase in cytochrome C in
supernatant and no increase in caspase 3 protein in
explant tissue. Interestingly, there may be a small but ben-
eficial effect of vancomycin in decreasing caspase 3 in
supernatants from treated tendon, mirroring the signifi-
cant reduction in the gene expression of caspase 3. Fur-
thermore, there was little evidence that vancomycin
induced any upregulation in apoptotic gene expression
compared with saline-treated grafts.
Figure 3. Vancomycin matrix gene and protein expression in tendon anterior cruciate ligament graft. Collagen1a, Collagen3a,
Decorin, and Tenacin C gene expression in tendon explant at 16 hours after 1-hour vancomycin treatment. Data are shown as
mean 6 SEM, normalized to the untreated tendon, relative to the housekeeping gene. N = 5. Collagen 1a protein is measured
by quantitative enzyme-linked immunosorbent assay. The tendon was treated for 1 hour, then incubated for 16 hours. Data
are shown as mean 6 SEM. N = 10; *P \ .05.
AJSM Vol. 49, No. 2, 2021 Vancomycin Wrap for ACL Surgery 431
The primary function of the tendon graft in ALCR is to
transfer mechanical load. Although the current study did
not directly measure the biomechanical properties of the
tendon graft after vancomycin treatment, histological stud-
ies indicate vancomycin treatment does not affect the
integrity of the graft structure. Furthermore, exploration
of the effect of vancomycin treatment on the matrix compo-
nent of the graft after treatment demonstrated no signifi-
cant difference in matrix gene expression compared with
untreated tendon or saline-treated tendon. It is important
to note, however, that there was a small but significant
reduction in collagen 1a protein release in vancomycin-
treated tendon supernatants compared with saline treat-
ment. It is postulated that this may demonstrate lower col-
lagen 1a protein breakdown from the tissue explant into
the supernatant after vancomycin treatment and thus
may reflect a positive effect of vancomycin treatment.
Vancomycin, as well as being antimicrobial, has also
been shown to have immune modulating potential. In
inflammatory mediated conditions, it has been shown to
act via alterations in the host T-cell population and lead
to reduced inflammation.1 In a sepsis model, however, van-
comycin was found to have proinflammatory effects on the
innate immune system.6 We therefore investigated the
inflammatory effect vancomycin had on tendon. Our results
show that vancomycin treatment reduced inflammatory
cytokine release from tendon compared with saline alone,
significantly IL-6. Previous work has shown that inflamma-
tion has a negative effect on the health of a tendon and IL-6
is involved in the development of tendinopathy.22 The ‘‘van-
comycin wrap’’ has the potential to create an anti-inflamma-
tory environment.
These results suggest vancomycin treatment is not detri-
mental to the cellular viability of the tendon graft but may
indeed have small beneficial effects pointing toward a homeo-
static molecular environment to encourage graft viability.
The reduction in collagen 1a release and inflammatory cyto-
kine release indicate reduced cellular stress and may be
linked with the reduction seen in the apoptotic gene expres-
sion of caspase 3. A recent retrospective cohort study
reviewed 1779 patients who underwent ACLR with vancomy-
cin soaking of the hamstring graft employed in 853 of these
cases. Over a 5-year period, whereby 100 patients were ran-
domly selected for follow-up each year, graft failure and re-
rupture rates were reported to be significantly lower in the
vancomycin wrap group; 8 failures out of 257 versus 16 fail-
ures out of 167 patients in the control group (P \ .01).25
Risk factors and prevention strategies for postoperative
infection in ACLR are multifactorial, with longer surgical
times and higher body mass index both shown to be inde-
pendent predictors.5 When infection rates are already low,
1 intervention alone may not consistently alter outcomes.
Figure 4. Inflammatory protein expression in tendon anterior cruciate ligament graft after vancomycin treatment. Interleukin 6 and
8, MMP3, and CCL2 protein in tendon supernatant, measured by quantitative enzyme-linked immunosorbent assay. The tendon
was treated for 1 hour, then incubated for 16 hours. Data are shown as mean 6 SEM. N = 10; *P \ .05.
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This was the conclusion in 1 study assessing the efficacy of
local vancomycin to spinal surgery wounds that reported no
difference in infection rates versus usual IV antibiotic pro-
phylaxis (1.61% vs 1.68%).32 Furthermore, infection after
ACLR can be caused by multiple pathogens that may not
be susceptible to vancomycin and the increasing use of 1
antibiotic as local prophylaxis may begin to select out for
non-Staphylococcal infections, which does not constitute
resistance but may have implications for clinical treatment
protocols should infection occur.17
Antibiotic resistance is an important consideration as
an increasing number of antibiotics are being used in the
perioperative period as prophylaxis. Data from cardiotho-
racic surgery using vancomycin paste in sternotomy
wounds have not found antibiotic resistance to be an issue
given that topical use does not lead to therapeutic serum
levels of the drug.20 Animal studies have demonstrated
that once wrapped in a vancomycin solution, the ACL graft
can act as a reservoir, continuing to release the drug over
24 hours at gradually decreasing levels, below a dose con-
sidered toxic to cells.15 Exposing tissues to prolonged sub-
therapeutic levels of a drug is a known way to establish
resistance.2 Future evaluation on the safety of the vanco-
mycin wrap in ACLR could include serum and synovial
drugs levels after surgery to investigate this.
There are limitations to this work, primarily with the
tendon explant model. There are many variables involved
in the vancomycin wrap during surgery: the volume of
antibiotic absorbed by the swab and by the graft, both
influenced by the volume of tissue and rinsing during the
arthroscopic procedure, and the effect of drying of the graft
before implantation under the lamina flow. It is challeng-
ing to create a model that encompasses all of these varia-
bles. We believe the model we used accurately reflects
the effect of the antibiotic alone on the graft. Further stud-
ies and clinical follow-up are recommended to investigate
the tendon graft biomechanical properties after treatment,
if there is any association with reduced graft failure and
any indications of antibiotic resistance.
CONCLUSION
No detrimental effect of vancomycin treatment was found in
terms of cellular apoptosis, matrix protein expression, and
inflammatory cytokine levels, compared with saline treat-
ment, in hamstring ACL graft. Additionally, data from the
current study provide minor indications for the beneficial
effect of vancomycin treatment on ACL graft integrity by pro-
moting a homeostatic molecular environment.
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